Shares of ImmunoGen (NASDAQ: IMGN), a small-cap biotech company focused on the development of antibody-drug conjugates for the treatment of cancer, plunged 24% in October, according to data from S&P Global Market Intelligence. The culprit for ImmunoGen’s miserable month looks to be none other than a common stock offering.